Superstring Capital Management
Latest statistics and disclosures from Superstring Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CYTK, NKTX, ETNB, BBIO, SVRA, and represent 42.70% of Superstring Capital Management's stock portfolio.
- Added to shares of these 10 stocks: NKTX (+$9.1M), CYTK (+$7.1M), SVRA (+$6.2M), CABA, BBIO, AVTE, APGE, DYN, PRAX, VRNA.
- Started 17 new stock positions in AUPH, AVTE, PYXS, DYN, APGE, PRAX, LYRA, ANNX, RNA, ASND. ALLK, TRML, ALPN, CTMX, CABA, PEPG, KALV.
- Reduced shares in these 10 stocks: , PTGX (-$8.7M), IMVT (-$8.6M), , LNTH, IONS, KROS, SLRN, KRYS, QTRX.
- Sold out of its positions in SLRN, FUSN, ImmunoGen, IMVT, KRYS, LNTH, NBIX, PTGX, QTRX, IMTX.
- Superstring Capital Management was a net buyer of stock by $8.0M.
- Superstring Capital Management has $151M in assets under management (AUM), dropping by 7.95%.
- Central Index Key (CIK): 0001931118
Tip: Access up to 7 years of quarterly data
Positions held by Superstring Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Superstring Capital Management
Superstring Capital Management holds 37 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Cytokinetics Com New (CYTK) | 12.9 | $20M | +57% | 279k | 70.11 |
|
| Nkarta (NKTX) | 8.5 | $13M | +242% | 1.2M | 10.81 |
|
| 89bio (ETNB) | 7.2 | $11M | -7% | 941k | 11.64 |
|
| Bridgebio Pharma (BBIO) | 7.2 | $11M | +71% | 354k | 30.92 |
|
| Savara (SVRA) | 6.8 | $10M | +153% | 2.1M | 4.98 |
|
| Ideaya Biosciences (IDYA) | 6.3 | $9.5M | -13% | 217k | 43.88 |
|
| Fate Therapeutics (FATE) | 4.5 | $6.8M | +8% | 921k | 7.34 |
|
| Day One Biopharmaceuticals I (DAWN) | 3.8 | $5.8M | -7% | 350k | 16.52 |
|
| Roivant Sciences SHS (ROIV) | 3.7 | $5.6M | +62% | 531k | 10.54 |
|
| Ionis Pharmaceuticals (IONS) | 3.5 | $5.2M | -36% | 121k | 43.35 |
|
| Marinus Pharmaceuticals Com New (MRNS) | 3.4 | $5.1M | +22% | 566k | 9.04 |
|
| Cabaletta Bio (CABA) | 3.3 | $5.0M | NEW | 291k | 17.06 |
|
| Urogen Pharma (URGN) | 2.9 | $4.3M | +12% | 288k | 15.00 |
|
| Verona Pharma Sponsored Ads (VRNA) | 2.8 | $4.2M | +109% | 259k | 16.09 |
|
| Aerovate Therapeutics (AVTE) | 2.2 | $3.3M | NEW | 110k | 29.57 |
|
| Apogee Therapeutics (APGE) | 2.0 | $3.0M | NEW | 45k | 66.45 |
|
| Axsome Therapeutics (AXSM) | 1.9 | $2.9M | +126% | 37k | 79.80 |
|
| Dyne Therapeutics (DYN) | 1.9 | $2.8M | NEW | 100k | 28.39 |
|
| Praxis Precision Medicines I Com New (PRAX) | 1.6 | $2.4M | NEW | 40k | 61.02 |
|
| Allogene Therapeutics (ALLO) | 1.5 | $2.3M | +134% | 521k | 4.47 |
|
| Keros Therapeutics (KROS) | 1.5 | $2.2M | -54% | 34k | 66.20 |
|
| Pyxis Oncology Common Stock (PYXS) | 1.4 | $2.1M | NEW | 494k | 4.26 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 1.3 | $1.9M | NEW | 13k | 151.17 |
|
| Pepgen (PEPG) | 1.1 | $1.7M | NEW | 114k | 14.70 |
|
| Tourmaline Bio (TRML) | 1.1 | $1.6M | NEW | 70k | 22.90 |
|
| Allakos (ALLK) | 1.0 | $1.6M | NEW | 1.2M | 1.26 |
|
| Cytomx Therapeutics (CTMX) | 1.0 | $1.5M | NEW | 679k | 2.18 |
|
| Annexon (ANNX) | 0.7 | $1.1M | NEW | 156k | 7.17 |
|
| Avidity Biosciences Ord (RNA) | 0.6 | $945k | NEW | 37k | 25.52 |
|
| Lyra Therapeutics (LYRA) | 0.6 | $904k | NEW | 145k | 6.22 |
|
| Inozyme Pharma (INZY) | 0.6 | $864k | -9% | 113k | 7.66 |
|
| Aurinia Pharmaceuticals (AUPH) | 0.3 | $494k | NEW | 99k | 5.01 |
|
| Kalvista Pharmaceuticals (KALV) | 0.3 | $380k | NEW | 32k | 11.86 |
|
| Alpine Immune Sciences (ALPN) | 0.2 | $358k | NEW | 9.0k | 39.64 |
|
| Spruce Biosciences (SPRB) | 0.2 | $346k | +270% | 440k | 0.79 |
|
| Ys Biopharma Ordinary Shares (YS) | 0.1 | $216k | 308k | 0.70 |
|
|
| So Young International Sponsored Ads (SY) | 0.1 | $199k | -77% | 183k | 1.09 |
|
Past Filings by Superstring Capital Management
SEC 13F filings are viewable for Superstring Capital Management going back to 2023
- Superstring Capital Management 2024 Q1 filed May 15, 2024
- Superstring Capital Management 2023 Q4 filed Feb. 14, 2024